Acquired vulvar lymphangioma: risk factors, disease associations, and management considerations: a systematic review

Acquired vulvar lymphangioma (AVL) is not well-characterized. Diagnosis is delayed and the condition is often refractory to therapy. OBJECTIVE: The objective of this study was to provide a systematic review of AVL including risk factors, disease associations, and management options. METHODS: A primary literature search was conducted using 3 databases: PubMed, CINAHL, and OVID, from all years to 2022. RESULTS: In total, 78 publications with 133 patients (48 ± 17 years) were included. Most studies were case reports/series. The most common disease association was prior malignancy (70 patients, 53% of cases) and inflammatory bowel disease (6 patients, 5% of cases). The most common malignancy was cervical cancer (57 patients, 43% of cases). Most patients had prior radiation or surgery, with 36% (n = 48) treated with radiation, 30% (n = 40) with lymph node dissection, and 27% (n = 36) with surgical resection. Common presenting symptoms included discharge/oozing, pain, and pruritus. Most patients underwent surgical treatment for AVL with 39% treated with excision, 12% with laser therapy (the majority used CO(2)), and 11% with medical therapies. Most patients had failed prior therapies and there was a diagnostic delay. LIMITATIONS: Retrospective nature. Most studies were limited to case reports and case series, with interstudy variability and result heterogeneity. CONCLUSION: AVL is an underrecognized entity and should be considered in patients with a history of malignancy or radiation to the urogenital area. Treatment should include multidisciplinary care and address underlying lymphatic changes, manage any existing inflammatory conditions, and utilize skin-directed therapies and barrier agents while addressing symptoms of pruritus and pain. Prospective studies are needed to further characterize AVL and develop treatment guidelines.